Sio Gene Therapies Announces Positive Interim Safety and Biomarker Data from Ongoing Phase 1/2 Clinical Study of AXO-AAV-GM1 Gene Therapy in GM1 Gangliosidosis
October 21, 2021 05:30 ET
|
Sio Gene Therapies
Consistent dose-dependent improvements across biomarker measuresNormalization of serum beta-galactosidase activity and GM1 ganglioside in CSF in the high-dose cohort No overt disease progression in...
UPDATE: Sio Gene Therapies to Present New Data at the European Society of Gene and Cell Therapy Virtual Congress 2021
October 04, 2021 09:04 ET
|
Sio Gene Therapies
NEW YORK, and DURHAM, N.C., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives...
Sio Gene Therapies to Present New Data at the European Society of Gene and Cell Therapy Virtual Congress 2021
October 04, 2021 07:30 ET
|
Sio Gene Therapies
NEW YORK and DURHAM, N.C., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of...
Sio Gene Therapies to Participate in Upcoming Conferences
September 23, 2021 07:30 ET
|
Sio Gene Therapies
NEW YORK and RESEARCH TRIANGLE PARK, N.C., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically...
Sio Gene Therapies Announces Dosing of First GM1 Gangliosidosis Early Infantile (Type I) Patient in Ongoing Phase 1/2 Study of AXO-AAV-GM1 Gene Therapy
September 09, 2021 07:00 ET
|
Sio Gene Therapies
- Study has now enrolled a total of nine patients across low-dose and high-dose cohorts- On track to report 12-month topline safety, biomarker, and efficacy data from Type II low-dose AXO-AAV-GM1...
Sio Gene Therapies Announces Corporate Updates and Fiscal First Quarter 2021 Financial Results
August 12, 2021 07:00 ET
|
Sio Gene Therapies
– Completed targeted enrollment of Type II patients in ongoing dose-escalation study of AXO-AAV-GM1 in GM1 gangliosidosis – On track to report 12-month topline safety, biomarker, and clinical...
Sio Gene Therapies Announces Fiscal Year 2020 Year-End Financial Results and Expected Fiscal Year 2021 Key Milestones
June 09, 2021 07:00 ET
|
Sio Gene Therapies
– Multiple GM1 gangliosidosis program milestones expected in FY2021, including 12-month data updates from the ongoing dose-escalation study and meeting with FDA to align on registrational pathway –...
Sio Gene Therapies to Present at the UBS Global Healthcare Virtual Conference
May 19, 2021 08:00 ET
|
Sio Gene Therapies
NEW YORK and RESEARCH TRIANGLE PARK, N.C, May 19, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve...
Sio Gene Therapies Announces CSF Reductions in GM1 Ganglioside from Clinical Trial of AXO-AAV-GM1 Gene Therapy
May 13, 2021 07:00 ET
|
Sio Gene Therapies
- GM1 ganglioside in CSF reduced in 4 out of 5 children treated with the lowest dose at 6 months follow-up- Direct evidence of biochemical effect in the CNS suggests intravenous gene therapy may...
Sio Gene Therapies Announces Four Upcoming Oral Presentations at the 24th Annual Meeting of the American Society of Gene and Cell Therapy
April 28, 2021 07:00 ET
|
Sio Gene Therapies
NEW YORK, and RESEARCH TRIANGLE PARK, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically...